Myocardial infarction triple rapid detection kit and preparation method for same

A technology for detection kits and kits, applied in the field of biotechnology applications, can solve the problems of incomplete indicators, delayed warning time, complicated operation, etc., and achieve the rapid effect of kits

Inactive Publication Date: 2014-07-30
GOLDBIOMARKERS DIAGNOSTICS +2
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Although there are reports on myocardial infarction detection kits, MPO detection kits and FABP3 detection kits in the prior art, there are corresponding shortcomings such as early warning time lag, long detection time, incomplete indicators, and complicated operations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Myocardial infarction triple rapid detection kit and preparation method for same
  • Myocardial infarction triple rapid detection kit and preparation method for same
  • Myocardial infarction triple rapid detection kit and preparation method for same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1. Preparation and detection of MPO-FABP3-CRP triple kit

[0046] 1 main material

[0047]1.1 MPO, FABP3 and CRP standard products: National Institute of Inspection and Quarantine; MPO, FABP3 and CRP specific paired antibody, goat anti-mouse IgG antibody: product of Beijing Shengqi Yanghuan Technology Co., Ltd.; chloroauric acid: product of Sigma Company; nitrocellulose (NC ) Membrane: SARTORIUS (Germany), CN140, product of Sartorius, Germany; bovine serum albumin (BSA), polyethylene glycol PEG20000, hydrolyzed casein: Sigma product; other commonly used reagents are analytical reagents.

[0048] 1.2 The clinical samples were obtained by the company in relevant hospitals, a total of 200 samples, including 100 serum samples, 50 plasma samples and 50 whole blood samples. The content distribution intervals of MPO, FABP3 and CRP were 6.25-400ng / ml and 3.125-200ng / ml respectively , 0.25-16 μg / ml.

[0049] 2 methods

[0050] 2.1 MPO antibody, FABP3 antibody and CRP ...

Embodiment 2

[0065] Example 2. Preparation of MPO-FABP3-cTnI Triple Kit

[0066] 1 main material

[0067] 1.1 MPO, FABP3 and cTnI standard products: National Institute of Inspection and Quarantine; MPO, FABP3 and cTnI specific paired antibody, goat anti-mouse IgG antibody: product of Beijing Shengqi Yanghuan Technology Co., Ltd.; chloroauric acid: product of Sigma Company; nitrocellulose (NC ) Membrane: SARTORIUS (Germany), CN140, product of Sartorius, Germany; bovine serum albumin (BSA), polyethylene glycol PEG20000, hydrolyzed casein: Sigma product; other commonly used reagents are analytical reagents.

[0068] 1.2 The clinical samples were obtained by the company in relevant hospitals, a total of 200 samples, 100 samples of serum, 50 samples of plasma and 50 samples of whole blood. Serum with a fixed value between 0.1 and 24.41ng / ml.

[0069] 2 methods

[0070] 2.1 MPO antibody, FABP3 antibody and cTnI antibody colloidal gold labeled trisodium citrate-tannic acid mixed reducing agent...

Embodiment 3

[0075] Example 3. MPO-FABP3-cTnI Triple Kit Serum Detection of Troponin Negative and Positive Patients

[0076] Randomly select 16 sera from patients with negative and positive troponin indicators, and proceed as follows:

[0077] 1) Equilibrate the detection reagent and sample to room temperature, take out the test paper card, and lay it flat;

[0078]2) Accurately draw 10 μl of serum sample, add it to a clean centrifuge tube, then dilute it 10 times with sample diluent (normal saline or PBS), and mix thoroughly;

[0079] 3) Use a pipette gun to draw 10 μl of the diluted sample and add it to the sample hole. Within 15 to 20 minutes, use a colloidal gold quantitative reader or a color card (half) to determine the quantitative results, see Table 1 below:

[0080] Table 1. MPO-FABP3-cTnI triple kit detection results of serum troponin negative and positive patients

[0081]

[0082]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a myocardial infarction triple rapid detection kit and a preparation method for the myocardial infarction triple rapid detection kit. The kit is formed by taking novel heart markers, that is, human myeloperoxidase (MPO) and heart fatty acid binding protein (FABP3) as basis, and matching with any of myocardial infarction markers CRP (C reactive protein), cTnI and Lp-PLA2. The kit is characterized by being capable of warning myocardial infarction diseases much earlier compared with the existing gold-label kit, and capable of warning the risk of the whole process before and after the occurrence of myocardial infarction. The kit is composed of a test paper card and a colour comparison card or a colloidal gold quantitative reading meter, wherein an anti-MPO specific antibody, an anti-FABP3 specific antibody and a colloidal gold pad resisting to any of other myocardial infarction markers are labelled on the test paper card simultaneously; and novel myocardial infarction markers are detected simultaneously by a colloidal gold immunochromatography technology at the first time, and the kit has the characteristics of being capable of realizing early warning and whole-course monitoring, simple and convenient to operate, rapid, suitable for field detection, economical and practical, and the like.

Description

technical field [0001] The patent of the present invention relates to the field of biotechnology applications, in particular to a triple rapid detection kit based on human myeloperoxidase (MPO) and cardiac fatty acid binding protein (FABP3) prepared by colloidal gold solid-phase immunochromatography. It is used for early warning of myocardial infarction and monitoring of treatment process and prognosis. Background technique [0002] Acute myocardial infarction (AMI) is a serious threat to human health, and early diagnosis and treatment of such diseases is one of the important means to reduce patient mortality. Especially when myocardial infarction with no obvious changes in the electrocardiogram, it is difficult to make an accurate diagnosis only by relying on the electrocardiogram, echocardiography and cardiac magnetic resonance. [0003] Cardiac markers refer to a series of biochemical substances that can be measured in blood, which can sensitively and specifically reflec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/558G01N33/573G01N33/6803G01N33/577G01N33/68G01N33/533G01N2800/324G01N2333/916G01N2333/4712G01N2333/70567G01N33/6893G01N2333/908G01N33/54388G01N33/54313G01N2333/47G01N2333/4704
Inventor 胡文波杨军李静
Owner GOLDBIOMARKERS DIAGNOSTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap